ANTARES PHARMA, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Revenue
Product sales
Development revenue
Licensing revenue
Royalties
Total revenue
Cost of product sales
Cost of development revenue
Total cost of revenue
Revenue, net
Product sales, net
Licensing and development revenue
Royalties
Total revenue, net
Operating expenses
Cost of product sales
Product sales, net
Licensing and development revenue
Cost of development revenue
Total cost of product sales
Gross profit
Research and development
Selling, general and administrative
Total operating expenses
Gain on sale of assets
Operating income
Other income (expense)
Interest expense
Other income (expense), net
Total other expense, net
Income (loss) before income taxes
Income tax provision (benefit)
Net income (loss)
Basic and diluted net loss per common share
Basic and diluted weighted average common shares outstanding
Earnings (loss) per common share
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted average common shares outstanding
Basic (in shares)
Diluted (in shares)

Comments